Adverum Biotechnologies Inc.

2.24-0.0100-0.44%Vol 375.72K1Y Perf -80.12%
Sep 23rd, 2021 13:32 DELAYED
BID2.24 ASK2.25
Open2.26 Previous Close2.25
Pre-Market- After-Market-
 - -%  - -
Target Price
5.00 
Analyst Rating
Strong Buy 1.38
Potential %
123.21 
Finscreener Ranking
★★★★     54.35
Insiders Trans % 3/6/12 mo.
-/100/27 
Value Ranking
★★★★     55.74
Insiders Value % 3/6/12 mo.
-/100/39 
Growth Ranking
★★     46.50
Insiders Shares Cnt. % 3/6/12 mo.
-/100/51 
Income Ranking
 —    -
Price Range Ratio 52W %
1.34 
Earnings Rating
Strong Sell
Market Cap219.80M 
Earnings Date
4th Nov 2021
Alpha0.02 Standard Deviation0.28
Beta1.13 

Today's Price Range

2.222.28

52W Range

2.0714.79

5 Year PE Ratio Range

-7.30-1.30

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
0.90%
1 Month
-4.26%
3 Months
-38.52%
6 Months
-77.16%
1 Year
-80.12%
3 Years
-61.86%
5 Years
-46.30%
10 Years
-

TickerPriceChg.Chg.%
ADVM2.24-0.0100-0.44
AAPL146.931.08000.74
GOOG2 842.4723.70000.84
MSFT300.141.56000.52
XOM57.041.83003.31
WFC48.081.00002.12
JNJ165.611.68001.02
FB346.743.53001.03
GE103.855.31005.39
JPM161.535.62003.60
Financial StrengthValueIndustryS&P 500US Markets
18.50
18.80
0.25
0.34
-
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
-
-1 834.20
-1 772.60
-13 415.90
-
RevenueValueIndustryS&P 500US Markets
7.50M
0.08
-48.48
-27.54
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.37-0.45-21.62
Q01 2021-0.38-0.2923.68
Q04 2020-0.32-0.39-21.88
Q03 2020-0.35-0.3111.43
Q02 2020-0.30-0.36-20.00
Q01 2020-0.27-0.31-14.81
Q04 2019-0.31-0.296.45
Q03 2019-0.27-0.257.41
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.40-17.65Negative
12/2021 QR-0.3612.20Positive
12/2021 FY-1.54-4.76Negative
12/2022 FY-1.4712.50Positive
Next Report Date4th Nov 2021
Estimated EPS Next Report-0.40
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume375.72K
Shares Outstanding98.13M
Shares Float92.40M
Trades Count1.87K
Dollar Volume9.19M
Avg. Volume1.93M
Avg. Weekly Volume2.94M
Avg. Monthly Volume1.73M
Avg. Quarterly Volume1.96M

Adverum Biotechnologies Inc. (NASDAQ: ADVM) stock closed at 2.25 per share at the end of the most recent trading day (a 0% change compared to the prior day closing price) with a volume of 541.98K shares and market capitalization of 219.80M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 114 people. Adverum Biotechnologies Inc. CEO is Laurent Fischer.

The one-year performance of Adverum Biotechnologies Inc. stock is -80.12%, while year-to-date (YTD) performance is -79.24%. ADVM stock has a five-year performance of -46.3%. Its 52-week range is between 2.07 and 14.79, which gives ADVM stock a 52-week price range ratio of 1.34%

Adverum Biotechnologies Inc. currently has a PE ratio of -1.60, a price-to-book (PB) ratio of 0.60, a price-to-sale (PS) ratio of 29.31, a price to cashflow ratio of 242.90, a PEG ratio of 2.32, a ROA of -31.56%, a ROC of -33.59% and a ROE of -40.80%. The company’s profit margin is -%, its EBITDA margin is -1 772.60%, and its revenue ttm is $7.50 Million , which makes it $0.08 revenue per share.

Of the last four earnings reports from Adverum Biotechnologies Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.40 for the next earnings report. Adverum Biotechnologies Inc.’s next earnings report date is 04th Nov 2021.

The consensus rating of Wall Street analysts for Adverum Biotechnologies Inc. is Strong Buy (1.38), with a target price of $5, which is +123.21% compared to the current price. The earnings rating for Adverum Biotechnologies Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Adverum Biotechnologies Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Adverum Biotechnologies Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.67, ATR14 : 0.14, CCI20 : -61.95, Chaikin Money Flow : -0.02, MACD : -0.07, Money Flow Index : 56.59, ROC : -3.85, RSI : 43.85, STOCH (14,3) : 31.91, STOCH RSI : 0.69, UO : 45.32, Williams %R : -68.09), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Adverum Biotechnologies Inc. in the last 12-months were: Dawn Svoronos (Buy at a value of $200 338), Laurent Fischer (Buy at a value of $395 941), Leone Patterson (Sold 25 066 shares of value $353 435 ), Patrick C. Machado (Buy at a value of $214 370)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (75.00 %)
6 (75.00 %)
4 (66.67 %)
Moderate Buy
1 (12.50 %)
1 (12.50 %)
0 (0.00 %)
Hold
1 (12.50 %)
1 (12.50 %)
2 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.38
Strong Buy
1.38
Moderate Buy
1.67

Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company. The company is committed to discovering and developing novel medicines that can offer potentially life-changing therapeutic benefit to patients living with rare diseases or diseases of the eye, who currently have limited or burdensome treatment options. Its services are focused on advancing three lead gene therapy programs to address unmet needs in wet age-related macular degeneration and in rare diseases alpha-1 antitrypsin deficiency and hereditary angioedema. Its leading programs include ADVM-022, ADVM-043 and ADVM-053.

CEO: Laurent Fischer

Telephone: +1 650 659-9323

Address: 800 Saginaw Drive, Redwood CIty 94063, CA, US

Number of employees: 114

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

70%30%

Bearish Bullish

62%38%

News

Stocktwits